NASDAQ: CAPR
Capricor Therapeutics Inc Stock Ownership - Who owns Capricor Therapeutics?

Insider buying vs selling

Have Capricor Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
George W. Dunbar Jr.Director2025-12-193,000$1.39
$4.17kBuy

1 of 1

CAPR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CAPR insiders and whales buy or sell their stock.

CAPR Shareholders

What type of owners hold Capricor Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Nippon Shinyaku Co Ltd15.51%7,090,351$216.68MInsider
Fountainhead Capital Partners Ltd12.14%5,551,000$169.64MInsider
Sinai Medical Center Cedars8.86%4,049,959$123.77MInsider
Eduardo Marban7.24%3,307,863$101.09MInsider
John Edward A. St6.78%3,101,574$94.78MInsider
Louis J. Grasmick6.43%2,937,729$89.78MInsider
Peter M. Kash6.39%2,920,446$89.25MInsider
Blackrock Inc6.24%2,850,978$87.13MInstitution
Wexford Capital LP5.70%2,606,778$79.66MInsider
Vanguard Group Inc5.60%2,561,880$78.29MInstitution

1 of 3

CAPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CAPR41.32%58.68%Net BuyingNet Buying
DFTX59.81%40.19%Net SellingNet Selling
RXRX61.48%13.63%Net SellingNet Selling
ZYME51.75%48.25%Net BuyingNet Selling
SRPT75.68%24.32%Net BuyingNet Selling

Capricor Therapeutics Stock Ownership FAQ

Who owns Capricor Therapeutics?

Capricor Therapeutics (NASDAQ: CAPR) is owned by 47.68% institutional shareholders, 67.72% Capricor Therapeutics insiders, and 0.00% retail investors. Nippon Shinyaku Co Ltd is the largest individual Capricor Therapeutics shareholder, owning 7.09M shares representing 12.33% of the company. Nippon Shinyaku Co Ltd's Capricor Therapeutics shares are currently valued at $221.15M.

If you're new to stock investing, here's how to buy Capricor Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.